Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3–amplified lung adenocarcinoma cells

Significance Our findings identify a type of oncogene addiction process driven by a lipid that controls prosurvival effector protein secretion. The crosstalk between functionally redundant phosphatidylinositol (PI) 4-kinases maintains addiction and can be targeted with small molecule kinase inhibitors that might be applicable to a genetically defined subset of cancers for which there are no effective targeted therapies. A chromosome 1q21.3 region that is frequently amplified in diverse cancer types encodes phosphatidylinositol (PI)-4 kinase IIIβ (PI4KIIIβ), a key regulator of secretory vesicle biogenesis and trafficking. Chromosome 1q21.3–amplified lung adenocarcinoma (1q-LUAD) cells rely on PI4KIIIβ for Golgi-resident PI-4-phosphate (PI4P) synthesis, prosurvival effector protein secretion, and cell viability. Here, we show that 1q-LUAD cells subjected to prolonged PI4KIIIβ antagonist treatment acquire tolerance by activating an miR-218-5p–dependent competing endogenous RNA network that up-regulates PI4KIIα, which provides an alternative source of Golgi-resident PI4P that maintains prosurvival effector protein secretion and cell viability. These findings demonstrate an addiction to Golgi-resident PI4P synthesis in a genetically defined subset of cancers.

[1]  P. Brown,et al.  PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma , 2020, Science Translational Medicine.

[2]  M. Waugh.  The Great Escape: how phosphatidylinositol 4-kinases and PI4P promote vesicle exit from the Golgi (and drive cancer). , 2019, The Biochemical journal.

[3]  Kwang-jin Cho,et al.  Depletion of phosphatidylinositol 4-phosphate at the Golgi translocates K-Ras to mitochondria , 2019, Journal of Cell Science.

[4]  M. D. De Matteis,et al.  The Golgi complex in disease and therapy. , 2018, Current opinion in cell biology.

[5]  S. Minogue.  The Many Roles of Type II Phosphatidylinositol 4‐Kinases in Membrane Trafficking: New Tricks for Old Dogs , 2018, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  Hualiang Jiang,et al.  PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells. , 2017, Cancer research.

[7]  M. Barbacid,et al.  A Braf kinase-inactive mutant induces lung adenocarcinoma , 2017, Nature.

[8]  B. Taylor,et al.  Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS , 2017, Nature.

[9]  G. Dobrikov,et al.  Allosteric Regulation of Phosphatidylinositol 4-Kinase III Beta by an Antipicornavirus Compound MDL-860. , 2017, ACS infectious diseases.

[10]  J. Jaggers.  New tricks for old dogs. , 2017, The Journal of thoracic and cardiovascular surgery.

[11]  R. Deberardinis,et al.  Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. , 2016, Cell reports.

[12]  S. Tavazoie,et al.  PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion. , 2016, Cancer cell.

[13]  Nicolas Stransky,et al.  Targeting cancer with kinase inhibitors. , 2015, The Journal of clinical investigation.

[14]  W. Sellers,et al.  Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure , 2015, EMBO reports.

[15]  M. Waugh.  Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer , 2014, Journal of Cancer.

[16]  L. Cantley,et al.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. , 2013, Cancer discovery.

[17]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[18]  Michelle M. Ng,et al.  GOLPH3 Bridges Phosphatidylinositol-4- Phosphate and Actomyosin to Stretch and Shape the Golgi to Promote Budding , 2009, Cell.

[19]  Martin M Matzuk,et al.  A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. , 2008, RNA.

[20]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.

[21]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[22]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[23]  M. Roth,et al.  Phosphatidylinositol 4 Phosphate Regulates Targeting of Clathrin Adaptor AP-1 Complexes to the Golgi , 2003, Cell.

[24]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[25]  J. Stephenson,et al.  Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia , 1983, Nature.